Under the terms of the agreement, Sun Pharma will have exclusive rights to commercialise Nidlegy™ for indications of skin cancers in the territories ...
Merck, a leading science and technology company, today announced that 43 abstracts covering several modalities and mechanisms will be presented at the 2023...
First Potential Approval of an Individualized, One-Time Cell Therapy for Patients with Advanced Melanoma Iovance Biotherapeutics, Inc. (NASDAQ: IOVA...
Positive clinical response as demonstrated in 8 out of 12 patients receiving EVX-01 in combination with a checkpoint inhibitor The study met prima...
— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results from the Phase III FRESCO...
New clinical development of a novel breast cancer diagnostic panel to “upstage” patients at time of diagnoses -BPGbio, Inc.,...
The Company has been granted permission from the Indian Central Drugs Standard Control Organization (CDSCO) to conduct its global, pivotal Phase 3 clinical...
Under the terms of the agreement, Aligos and Amoytop will collaborate on the research and development of oligonucleotide compounds for the treatment of liv...
As a Siemens Healthineers company, Varian is working to connect the cancer care continuum to empower clinicians to deliver more efficient, more personalize...
UCB's expertise in macrocyclic peptide discovery, using its proprietary mRNA-display platform, ExtremeDiversity™, will aid Ariceum's discovery of t...
Collaboration will leverage Bicycle Therapeutic’s synthetic peptides for the discovery and development of multiple targeted radioconjugates of the ...
Increasing localized access can provide faster results for patients while potentially improving patient outcomes Agreement aims to enable greater access...
Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. jointly announced that the IND application was approved in China for t...
Pancreatic adenocarcinoma (PDAC) is one of the most deadly forms of cancer, in part due to the majority of diagnoses being late-stage; the five-year surviv...
© 2024 Biopharma Boardroom. All Rights Reserved.
